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Abstract

Viral injection of RNA polymerase II-interacting protein RPRD2 in the nucleus accumbens
induces anxiety-like behavior in mice
Hannah E. Woolard
A thesis in partial fulfillment of the requirements for the degree of Master’s in Science in
Anatomy and Neurobiology at Virginia Commonwealth University
Virginia Commonwealth University, 2022
Peter J. Hamilton, Ph.D., Assistant Professor, Department of Anatomy and Neurobiology

Anxiety and its related disorders have become increasingly prevalent as more awareness
and acceptance of mental illnesses have come to fruition, especially in the light of the ongoing
COVID-19 pandemic. Anxiety can affect anyone regardless of their age, sex, or social status and
is currently the most commonly diagnosed mental illness worldwide (Bandelow & Michaelis,
2015). While there are several effective treatments available, the underlying brain mechanisms
that cause anxiety are still largely unknown and further research continues to piece together the
complex pathophysiology behind this disease. The use of laboratory animal models, such as
mice, to induce and observe anxiety-like behaviors are an effective research method to determine
specific molecular mechanisms that can influence anxiety. These studies may help to identify
more effective treatments and improve the understanding of complex mental illnesses.
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Our laboratory previously identified increased levels of protein expression of RPRD2 in
the nucleus accumbens (NAc) of mice that were resilient to chronic social defeat stress
(Hamilton et al., 2020). Known as regulation of nuclear pre-mRNA domain containing protein 2,
this protein is largely unstudied and its mechanism and function remain incompletely
understood. RPRD2 is a member of the RPRD family of proteins, which are known to
downregulate transcription through interaction with the c-terminal domain of RNA polymerase II
(Ali et al., 2019; Ramani et al., 2021). This thesis project began by exploring the specific effects
of RPRD2 in the NAc of C57BL/6J mice, and while the initial hypothesis was that RPRD2
overexpression would make mice resilient to social defeat stress, it was subsequently found that
there is a relationship between RPRD2 expression and anxiety-like behaviors.
To study this protein, a viral vector was created by inserting cDNA encoding RPRD2 into
a destination vector using a LR clonase reaction. By packaging this plasmid within herpes
simplex virus (HSV) and injecting mice with this viral RPRD2 in the NAc, it was observed that
there was an increase in anxiety-like behavior such as avoiding the open arms of the elevated
plus maze. These behaviors were noted regardless of whether these mice previously experienced
chronic social defeat stress. However, the viral RPRD2 did not have any significant effects on
the social behaviors of mice in the social interaction test, even when the mice were exposed to an
accelerated chronic social defeat stress paradigm. This thesis proposed a potential mechanism for
RPRD2 through binding to the c-terminal domain of RNA polymerase II. Once RPRD2 binds, it
is thought to pause the progression of transcription to the elongation phase by dephosphorylating
Serine 5. While more research must be performed to confirm this mechanism, the data from this
thesis suggests that the injection of HSV-RPRD2 in the NAc increases anxiety-like behavior in
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mice. The results of this study will help to better understand one potential mechanism of anxiety
as well as provide more insight to the in vivo function of the protein RPRD2.
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Introduction

Generalized Anxiety Disorders
Mental illnesses have a high level of prevalence in the United States, with millions of
people affected each year. The most commonly diagnosed mental illnesses are anxiety disorders
that include generalized anxiety disorder (GAD), social anxiety disorder (SAD), and specific
phobias (Bandelow & Michaelis, 2015). Anxiety disorders are commonly comorbid with other
mood disorders such as major depression or bipolar and are often seen in individuals who have
chronic medical illnesses (Hidalgo & Sheehan, 2012). It is estimated that a third of the
population will be diagnosed with an anxiety disorder in their lifetime, with roughly twice as
many women being diagnosed than men (Bandelow & Michaelis, 2015). While most anxiety
disorders will be diagnosed by the age of 20, GAD is more prevalent in middle-age with an
average onset at the age of 31 (Wittchen & Hoyer, 2001; Bandelow & Michaelis, 2015). As the
negative stigma associated with mental health is decreasing, these numbers may increase as
people feel more comfortable seeking help and having honest conversations about their
symptoms.
Acute episodes of anxiety can be beneficial to human performance and productivity, but
the presence of chronic anxiety can have disabling effects. GAD is characterized by symptoms
such as enduring worrying, restlessness, and excessive anxiety that persists but is not linked to
stressful events (Wittchen & Hoyer, 2001). GAD and other anxiety disorders can also be
associated with physical symptoms such as sweating, increased heart rate, and fatigue. High
levels of anxiety can impact a person’s ability to think clearly, finish tasks, and respond
appropriately, leading to problems in relationships, employment, and overall health (Brahmbhatt
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et al., 2021). Anxiety disorders are also commonly misdiagnosed due to the variability of
symptoms shown and the comorbidities present (Brahmbhatt et al., 2021; Bandelow &
Michaelis, 2015). There are currently several effective treatments for anxiety such as cognitive
behavioral therapy (CBT), selective serotonin reuptake inhibitors (SSRIs), benzodiazepines, and
several others that can relieve the symptoms of anxiety (Brahmbhatt et al., 2021). The average
remission rate of patients across all treatments is estimated at roughly 51 percent, meaning that
about half of people seeking treatment for anxiety do not experience long-term relief (Springer et
al., 2018). Despite the high rate of people diagnosed with anxiety disorders, the underlying
mechanisms are still unclear and require further research to improve the long-term effectiveness
of treatments to GAD and other anxiety disorders.

Animal Models of Anxiety
The high disease burden of anxiety has necessitated the development of multiple animal
models useful for the study of anxiety disorders. These models are created through conflict that
create approach-avoidance behaviors and are beneficial to the discovery of the mechanisms of
anxiety and the clinical effects of drugs (Campos et al., 2013). One of the more common subjects
for these tests are rodents, although other animals can be used effectively. For the purposes of
this thesis project, the focus will be on social defeat, the social interaction test, the elevated plus
maze, and the open field test.
Chronic social defeat stress (CSDS) is a paradigm where a novel male C57B/6J mouse is
introduced into the home cage of an aggressor male CD-1 mouse. This animal model of
prolonged social stress has aided in understanding underlying mechanisms for disorders such as
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anxiety or depression (Golden et al., 2011). This model takes a C57BL/6J mouse and repeatedly
exposes it to an aggressor CD-1 mouse. While this physical exposure only takes place for about
ten minutes, the mice are continuously exposed to sensory stress by being placed in a cage with a
CD-1 aggressor present but separated by a perforated divider (Golden et al., 2011). This
experience is repeated once a day for ten days, however there are multiple modifications to this
experiment that remain effective in causing mice to be “defeated” such as the accelerated CSDS.
The bouts of social defeat experienced by the C57BL/6J mouse leads to anxious and depressive
behavior in a majority of mice.
The social interaction (SI) test can be used to measure social behavior in mice after they
experience CSDS. The SI test measures for social deficits and anxiety-like behaviors in mice and
is thought to mimic the state of anxiety similar to that experienced in GAD (File & Seth, 2003).
C57BL/6J mice will be placed into an open field arena for 2.5 minutes, then have another 2.5
minutes in the same field with a novel CD-1 aggressor mouse present in a cage. Mice will be
defined as susceptible if they spend less time in the interaction zone, the zone near the CD-1
mouse, when the CD-1 is present in comparison to when it is absent. Mice will be defined as
resilient if they spend more time in the interaction zone when the CD-1 mouse is present (Golden
et al., 2011). Susceptible and resilient mice are associated with social interaction (SI) ratios
which are calculated by dividing the time spent in the interaction zone when the CD-1 is present
by the time spent in the interaction zone when the CD-1 is absent. SI ratios less than 1 are used
to define the mouse as susceptible and SI ratios greater than 1 are resilient mice (Golden et al.,
2011). The zones are defined by digital animal tracking technology (Ethovision XT) and include
corner zones, the interaction zone, and a center zone.
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The elevated plus maze (EPM) is used to measure innate anxiety in mice. This test is
based on rodents’ instinctive tendency to explore their environment and the natural avoidance of
bright, open, and elevated spaces (Campos et al., 2013). The EPM is also used to measure
anxiety-like behavior in mice and has been found to have a strong predictive validity in defining
brain regions and mechanisms involved in anxiety (Walf & Frye, 2007). This apparatus is raised
above the ground and consists of four “arms,” with two enclosed arms that are opposed
perpendicular to two open arms. Mice that spend greater amounts of time in the closed arms are
thought to be more anxious or stressed than mice who visit the open arms of the EPM (Kraeuter
et al., 2019). This test does not require any prior conditioning and is effective in measuring
anxiety-like behavior in mice.
The open field test is another test that is utilized to measure anxiety-like behavior in
rodents. If a mouse spends less time in the center of the open field, they are deemed to be more
anxious (Walz et al., 2016). This is associated with a behavior known as thigmotaxis, which is
defined as the tendency of mice to stay close to the walls of an open space when exploring.
Thigmotaxis and decreased time in the center are well-established markers of increased anxietylike behavior in rodents (Walz et al., 2016). These tests have a high effectiveness in recreating
anxiety-like behavior in mice that are useful in determining mechanisms of action and
pharmacological agents.

The Nucleus Accumbens
The nucleus accumbens (NAc) is commonly referred to as the reward circuit of the brain
due to its interconnectedness with the limbic system. The NAc can be divided into two sections
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anatomically, the core in the center and the outer shell. These sections are chemically and
molecularly diverse from each other and are thought to have different functions; the core
involved in learning and purposeful action selection during goal-directed behaviors, while the
shell is involved with emotional and motivational responses (Baik, 2020). Although the NAc is
known for its involvement in the reward circuit, the NAc is also involved in behavioral responses
to both aversive and rewarding stimuli. In a human study, fMRI was used in individuals with
high levels of anxiety, and it showed an increase of activation when the stressor could be actively
avoided by performing a behavior (Levita et al., 2012). However, there is a decrease in activation
of this brain region when the individual can passively avoid a stressor by omitting a behavior,
showing the influence of NAc in influencing motivated behaviors (Levita et al., 2012).
The NAc are largely composed of GABAergic medium spiny neurons (MSNs) that
express dopamine D1 receptors or D2 receptors (Baik, 2020). Since the NAc is a critical
component of the reward circuitry in the brain, it plays a key role in regulating anxiety (Xiao et
al., 2020). The NAc receives input from limbic systems such as the amygdala, hippocampus, and
prefrontal cortex and responds to stress signals (Li et al., 2021). While D1 and D2 MSNs make
up a majority of the NAc, studies have shown that parvalbumin interneurons in the NAc have a
major effect on anxiety-like behaviors (Xiao et al., 2020). However, due to the complexity of
anxiety, there are likely many factors that result in this behavior and should be analyzed to
provide more effective treatments. Anxiety is the most prevalent mental disorder, and avoidance
behavior is a central symptom that contributes to further perpetuating the anxious state (Xiao et
al., 2020).
Disruption in the NAc has been linked to depressive behaviors. A study on rats who
experienced high levels of anxiety showed that the NAc had decreased arborization, shorter
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dendrites, and lower spine density (Gebara et al., 2021). Their MSNs also had reduced excitatory
inputs and lower connectivity between cells (Gebara et al., 2021). A balance between the activity
of D1-MSNs and D2-MSNs is thought to be crucial for normal behaviors, and the disruption of
this is thought to be involved in the pathophysiology of major depressive disorder, OCD, and
bipolar disorder (Baik, 2020). Deep-brain stimulation of the NAc can alleviate symptoms in
treatment resistant OCD patients and addiction patients, showing its importance in the
mechanisms of these diseases (Levita et al., 2012). In addition, studies have shown that
molecular changes in the cells caused by chronic stress or high levels of anxiety can be reversed
through antidepressant treatment (Gebara et al., 2021). The NAc plays a key role in the
pathophysiology of anxious and depressed individuals and targeting of this brain region can
regulate these behaviors.

RNA Polymerase II Function
RNA Polymerase II (Pol II) is an important component of transcription in all eukaryotic
cells. Pol II is an enzyme that catalyzes and directs the synthesis of messenger RNA (mRNA)
from a DNA template (Cramer, 2004). The transcription cycle has three main phases: initiation,
elongation, and termination. In order for initiation to occur, five general transcription factors
TFIIB, -D, -E, -F, and -H are required to recognize the promoter region to unwind the DNA and
form the “transcription bubble” (Figure 14A) (Liu et al., 2013). These transcription factors bind
to the TBP and form a transcription initiation complex with Pol II. Following the initiation of
transcription, Pol II continues to move along the template to elongate the transcript one
nucleotide at a time from 5’ to 3’ (Figure 14A) (Corden, 2021). The enzyme can maintain the
bubble, translocate along the template DNA, synthesize RNA, and proofread the nascent RNA
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independently (Cramer, 2004). Once Pol II reaches the 3’ end of the transcript, it releases the
completed transcript and terminates transcription. Each step of transcription can be influenced by
proteins that interact with the C-terminus of the largest subunit (Corden, 2021).
Pol II has a mass over 500 kDa and consists of twelve subunits that have unique
interactions and composition (Woychik & Young, 1990). Of the twelve subunits, the first three
(Rpb1, Rpb2, and Rpb3) are the largest. A number of different proteins can interact with this
enzyme, especially the carboxy-terminal end of one subunit, to regulate its activity and
production of the type and quantity of RNA transcripts formed in response to a cell’s
requirements (Woychik & Young, 1990). The C-terminal domain (CTD) protrudes off Pol II
subunit Rpb1 and consists of 52 heptapeptide repeats with the sequence Tyr-Ser-Pro-Thr-SerPro-Ser (Cramer, 2004). Various signals known as post-translational modifications (PTM) can
phosphorylate or dephosphorylate heptapeptide repeats of the CTD which correspond to different
parts of the transcription cycle such as initiation, elongation, and termination (Ramani et al.,
2021). PTM of the CTD are crucial to coordinating and organizing the events of transcription
and proper gene expression.
Patterns of CTD phosphorylation regulate a specific interaction with RNA processing
factors; for example, recycling of Pol II after termination requires dephosphorylation of the CTD
(Cramer, 2004). The phosphorylation of Serine-5 (Ser5) is required for Pol II to be released from
the promoter region and progress to the elongation phase of transcription (Clark, 2010). Ser5
phosphorylation peaks around the transcription start site and is gradually removed by
phosphatases as Pol II elongates (Hsin & Manley, 2012). Proteins that interact with the CTD can
be involved in various transcriptional steps, demonstrating that this region of Pol II is crucial in
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regulating the cycle. Loss of the CTD results in decreased efficiency and or the loss of all
processing steps (Clark, 2010).

Regulation of Nuclear Pre-mRNA Domain Containing Protein 2
Regulation of cellular processes such as gene expression is critical to the function and
survival of the cell. Pol II is the enzyme responsible for transcribing all protein-coding regions of
DNA. Once Pol II is recruited to the gene promoter, different factors can affect the rate at which
RNA is transcribed. There is a rate-limiting step found in higher eukaryotes known as promoterproximal pausing that is associated with specific phosphorylation events at the CTD of Pol II
(Winczura et al., 2021). There are many factors that interact with the CTD to affect transcription,
to include the RPRD (Regulation of Nuclear Pre-mRNA Domain) family of proteins (RPRD1A,
RPRD1B, and RPRD2). RPRD1A and RPRD1B contain similar structures and coiled-coil
domains that facilitate their interaction with the CTD (Winczura et al., 2021). Proteins containing
CTD-interacting domains (CID) such as RPRDs have an affinity for lysine residues that are
acetylated (i.e., K7ac) (Ali et al., 2019). This interaction promotes Ser5 dephosphorylation,
which pauses transcription by preventing Pol II from moving into the elongation phase of
transcription (Ali et al., 2019; Ramani et al., 2021). This process is thought to be the main
mechanism of RPRDs to downregulate transcription.
While RPRD1A and RPRD1B are known paralogs, their functions are quite different
(Winczura et al., 2021). RPRD1B is associated with cell proliferation and tumors, while
increased expression of RPRD1A slows cell growth and suppresses tumor growth (Winczura et
al., 2021). RPRD2 is much larger than its counterparts with little known about its function.
RPRD2 is also known as REAF, or RNA-associated early-stage antiviral factor. In comparison to
16

its counterparts, RPRD2 has serine- and proline-rich domains, with the latter region becoming
hyperphosphorylated during M phase (Ni et al., 2011). RPRD family proteins are all involved in
transcription, but RPRD2 may have a specific role in microRNA biogenesis. RPRD2 is regulated
by Interleukin-32a (IL-32a), an anti-inflammatory cytokine. IL-32a can regulate RPRD2 to
suppress miRNA synthesis when the cells are experiencing inflammation (Son et al., 2017).
RPRD2 has become prominent in human immunodeficiency virus (HIV) research. This
protein can restrict HIV replication and limit integration of the virus into the genome (Gibbons et
al., 2020). Research has shown that RPRD2 acts early post-entry of HIV and can block the virus
during or following initiation of reverse transcription, before the virus can enter the nucleus
(Marno et al., 2014). However, HIV type 1 contains an accessory protein known as Vpr that
targets RPRD2 for degradation to overcome this restriction and successfully infect cells
(Gibbons et al., 2020). If the level of RPRD2 in a cell decreases, then the cell is more susceptible
to infection by HIV. RPRD2 can interact with both cellular and viral nucleic acids and the
protein has the capability to target incoming viral RNA or genomes (Marno et al., 2014). While
the exact mechanism in this interaction is not yet fully understood, it is important to note that
RPRD2 can bind to the CTD. The data from these studies (Gibbons et al., 2020, Marno et al.,
2014) demonstrate that RPRD2 is an active component in restricting HIV from infecting the cell
and a potential treatment may be increasing levels of RPRD2 in cells to overcome the effects of
Vpr.

RPRD2 and its Role in Anxiety

17

In a previous study from the Hamilton group, higher levels of RPRD2 were found in the
NAc, ventral hippocampus, and medial prefrontal cortex of mice that were resilient to CSDS
(Hamilton et al., 2020). This led to the question of whether RPRD2 played a role in stress-related
behaviors. While there is knowledge that RPRD2 functions by influencing Ser5
dephosphorylation to pause transcription initiation (Ali et al., 2019; Ramani et al., 2021), there
are no current studies that focus on the relationship between this protein and stress-related
behaviors.
Given the preliminary data from Dr. Hamilton’s research (2020), the hypothesis was that
higher levels of the protein RPRD2 in the NAc would protect against stress-induced behavioral
adaptations, including social deficits and anxiety-like behaviors. However, this hypothesis was
rejected based on the observation within this thesis that viral injection of RPRD2 did not
improve stress-induced social deficits and actually precipitated a worsening of anxiety-like
behaviors. The increase in anxiety behaviors occurred regardless of exposure to CSDS and was
dependent on the injection of viral RPRD2. These data below will improve the understanding of
the function of the protein RPRD2 and propose one potential brain mechanism for the onset of
anxiety disorders. Thus, one can conclude that elevated levels of RPRD2 in the NAc observed in
resilient C57/B6 mice (Hamilton et al., 2020) is likely not driving resilient behaviors and is being
compensated for by other brain mechanisms in these behaviorally resilient animals. Further
understanding of the mechanisms for anxiety disorders will improve the treatment available by
targeting specific factors that contribute to its onset. In addition, this data will contribute to the
knowledge of the functionality of RPRD2.
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Materials and Methods
Animal Husbandry
This study used adult male C57BL/6J mice aged 8-11 weeks of age and 6-month-old CD1 retired male breeders (CD-1 aggressors) from Jackson Laboratories. All animals were housed
in a temperature (22-25°C) and humidity-controlled colony room in static cages. C57BL/6J mice
were group housed with five to a cage and CD-1 aggressor mice were housed individually. The
room was kept on a 12-hour light/dark cycle with lights on at 7 a.m. and lights off at 7 p.m. Mice
were provided standard food and water that was freely available. All studies were conducted in
accordance with the Institutional Animal Care and Use Committee of Virginia Commonwealth
University and National Institutes of Health Guide for the Care and Use of Laboratory Animals,
and all relevant guidelines and regulations were followed.

Viral Vectors
RPRD2 was inserted into the p1005 plasmid using an LR reaction. The ThermoFisher
Scientific gateway LR Clonase II cloning protocol from the ThermoFisher Scientific website was
followed and the Gateway LR Clonase II Enzyme mix kit was used (catalog number 11791-020
and 11971-100). RPRD2 was confirmed to be inserted correctly via sanger sequencing
(GENEWIZ; New Jersey) (Figure 1). Colonies containing RPRD2 were chosen, and a miniprep
(catalog number 27106) and maxiprep (catalog number 12163) were performed following the kit
protocol from QIAGEN to amplify the bacteria for viral packaging into the herpes simplex virus
(HSV). Samples were then shipped to the Gene Delivery Technology Core at Massachusetts
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General Hospital for viral packaging. Once packaged, aliquots were made and stored in -80
degrees Celsius to be used in viral gene transfer through stereotaxic surgery.

20
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Figure 1: RPRD2 inserted into p1005 plasmid. Gateway cloning used an LR reaction to insert
RPRD2 into a p1005 destination vector flanked by attB sites. This DNA clone was confirmed via
sanger sequencing and packaged into a viral vector to be used in stereotaxic surgery.
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Stereotaxic Surgery
Stereotaxic surgeries targeting the NAc were performed. Mice were anesthetized with a
mixture of ketamine (100 mg/kg) and xylazine (5 mg/kg) dissolved in sterile water. Mice were
positioned in a stereotaxic instrument (Kopf model 942) and the skull surface was exposed. The
NAc was targeted bilaterally (Bregma: anterior-posterior: +1.6, medial-lateral: +1.5, dorsalventral: -4.4) at 10° from the midline. Hamilton syringes (5 μl; catalog number 84851) were used
to infuse a total of 1.0 μl of virus. The virus was delivered at a rate of 0.1 μl per minute, followed
by a five-minute break to allow the virus to diffuse in the tissue. In all experiments, proper NAc
targeting was confirmed via tissue analysis of the needle track and GFP expression. After
surgery, the mice were allowed to recover for 24 hours prior to the accelerated CSDS. Mice in
the group without CSDS had three days to recover before behavior analysis. Mice were
monitored for any signs of distress such as lack of grooming, weight loss, and altered
locomotion. Surgeries were completed with aid from Joseph Picone, Natalie Truby, and
Gabriella Silva, trained graduate students in the Hamilton Lab.

Chronic Social Defeat Stress
Mice were then divided into three different groups. The first group of C57BL/6J mice
(n=20) experienced a five-day accelerated CSDS (Figure 2B), the second group (n=20)
experienced a six-day accelerated CSDS (Figure 2C), and the last group (n=20) did not
experience CSDS (Figure 2A). Two different lengths of CSDS were used in the effort to
precipitate a stronger defeat experience in the hopes of visualizing a significant difference in
resilience levels for mice injected with HSV-RPRD2. For each group, half were injected (n=10)
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with viral RPRD2 into the NAc and the other half (n=10) were injected with viral GFP as a nonfunctional control.
The experiment utilized an accelerated CSDS protocol (Figure 3A). CD-1 retired breeder
mice were screened for aggressive behavior for three-minute intervals over three days. CD-1
mice that consistently physically dominated male C57BL/6J screener mice were used as
aggressors for the study. C57BL/6J mice were exposed for five or six consecutive days to an
aggressive novel CD-1 retired breeder for 11 minutes twice a day, with one encounter in the
morning and one in the afternoon to allow mice time to recover after each encounter. In each
defeat session, the male C57BL/6J mouse would be placed in the home cage of a CD-1 aggressor
mouse to be aggressed upon. With every exposure, the C57BL/6J mouse encountered a novel
CD-1 aggressor. After the defeat, C57BL/6J mice were then separated from the aggressor by a
perforated divider within the same cage to maintain constant contact and sensory stress with the
CD-1 aggressor present. After the final defeat took place, C57BL/6J mice were moved to
individually housed cages for 24 hours. Two mice (One HSV-GFP, one HSV-RPRD2) from the
five day CSDS group (Figure 2B) and four (Three HSV-GFP, one HSV-RPRD2) mice from the
six day CSDS group (Figure 2C) received injuries that necessitated their removal from the
defeat protocol and were not analyzed in the behavior study.

Behavior Analysis
Twenty-four hours after the final defeat (or 3 days after surgery for the group that did not
experience CSDS) mice were tested in the SI, EPM and the open field tests. Group 1 (Figure
2B) tested 18 mice (HSV-RPRD2 n=9, HSV-GFP n=9), group 2 (Figure 2C) tested 16 mice
24

(HSV-RPRD2 n=9, HSV-GFP n=7), and group 3 (Figure 2A) tested 20 mice (HSV-RPRD2
n=10, HSV-GFP n=10). These tests took place on the same day due to the short expression
period of HSV. SI (Figure 3B) took place by first allowing mice to habituate and explore an
open arena with a wire mesh cage (interaction zone) centered against one wall for 2.5 minutes.
Data acquired from the first 2.5 minute period without the CD-1 aggressor present was used to
measure thigmotaxis data as the open field test. Then, the mouse returned to the arena for another
2.5 minutes with a novel CD-1 present in the wire mesh cage. This CD-1 aggressor was not used
in CSDS to determine consistent SI for all C57BL/6J mice. The arena was wiped clean with 70%
EtOH before a new C57BL/6J mouse was placed in the arena. Data were then analyzed as time
spent in the interaction zone without the aggressor compared to time spent within the interaction
zone with the aggressor present. This data were then calculated into SI ratios by taking the time
the C57BL/6J mouse spent in the interaction zone with the CD-1 mouse present and dividing it
by the time spent in the interaction zone with the CD-1 absent (SI ratio = time in IZ target
present / time in IZ target absent). Total distance moved by the C57BL/6J mouse was recorded
and evaluated when the target was absent.
Mice were then tested in an EPM to measure non-social related anxiety. EPM testing was
performed about 20-30 minutes after SI. The EPM apparatus (Figure 3C) is constructed of black
Plexiglass and consists of two open arms and two closed arms connected by a central platform
(10 x 10 cm). Open and closed arms are perpendicular to each other and are 30 cm in length and
5 cm in width. Alternating arms are enclosed with opaque walls that are 40 cm in height. The
other arms that have no walls have raised edges that are about 1 cm to ensure that the mouse
does not fall off the maze while exploring. The maze is elevated 60 cm off the floor. C57BL/6J
mice were placed in the center of the maze and their exploration was tracked for five minutes.

25

The platform of the EPM was wiped clean with 70% EtOH after each trial prior to a new
C57BL/6J mouse entering the maze. All behavior tests took place in a red-light room, where no
defeats took place, and were monitored and recorded by Ethovision XT (Noldus Information
Technologies; Leesburg, VA). Behavior analysis was performed with the help of Claire Atiyeh, a
master’s student in the Hamilton Lab.
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Figure 2: Overview of study. A) Group one did not experience CSDS. Three days after
stereotaxic surgery mice were tested for behavior and sacrificed; n=10 HSV-RPRD2 and n=10
HSV-GFP mice. B) Group two experienced a five-day accelerated CSDS with two defeats per
day for 10 minutes each; n=9 HSV-RPRD2 and n=9 HSV-GFP. Behavior analysis occurred 24
hours after the final defeat and the animals were sacrificed to collect tissue. C) Group three
experienced a six-day accelerated CSDS with two defeats per day for 11 minutes each; n=9
HSV-RPRD2 and n=7 HSV-GFP. Behavior analysis occurred 24 hours after the final defeat and
the animals were sacrificed to collect tissue.
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Figure 3: CSDS, SI and EPM. A) Accelerated CSDS paradigm. C57BL/6J mice are placed in the
home cage of a CD-1 aggressor twice daily for 10 minutes each. After the defeat period, they are
placed on the other side of the cage separated by a perforated divider. B) The SI test gives
C57BL/6J mice 2.5 minutes to explore the open field by themselves, and 2.5 minutes to explore
with a CD-1 aggressor present in a cage in the interaction zone. Time spent in each zone is
recorded by Ethovision XT. Center zone data taken from the first 2.5 minutes was used to
measure thigmotaxis in C57BL/6J mice. C) C57BL/6J mice explore the EPM for a five minute
period. The time spent in the closed arms of the maze is recorded by Ethovision XT. Created
using BioRender.com.
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Tissue Extraction
Half an hour after behavioral testing, NAc tissue was collected from rapidly cervical
dislocated and decapitated animals without anesthesia. Brains were removed one at a time and
promptly sectioned into 1 mm coronal slices using a brain matrix. Bilateral tissue punches from
the NAc (12 gauge; internal diameter, 2.16 mm) were frozen on dry ice and immediately stored
at -80°C. The anatomically correct presence of GFP in the NAc was confirmed visually through
dissection and mice with weak or incorrect expression were excluded from the results. One
mouse (HSV-GFP) was excluded from the first group (Figure 2B) for faint expression, two mice
(both HSV-RPRD2) were excluded from the second group (Figure 2C) for undetectable
expression, and five mice (four HSV-RPRD2, one HSV-GFP) were excluded from the third
group (Figure 2A) for faint expression. Tissue extraction and sacrificing of the mice was
performed with help from Joseph Picone, Gabriella Silva, Claire Atiyeh and Natalie Truby,
trained graduate students in the Hamilton Lab.

Western Blotting
Western blots were performed from tissue samples of mice that did not experience CSDS
(Figure 2A) and the five day accelerated CSDS (Figure 2B) groups. Protein was extracted from
bilateral NAc punches and was suspended in a RIPA sample and 2x Laemmli buffer. Next, 15 μl
of each sample and 10 μl of the well standards (Precision Plus Protein Unstained Standards and
the Precision Plus Protein Kaleidoscope, BIO-RAD) were run on a TGX (Tris-Glycine
eXtended) stain free gel (BIO-RAD; catalog number 5678094) at 100 V for 2 hours. The protein
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was then transferred to a membrane using Trans Blot Turbo Packs (BIO-RAD; catalog number
1704157) in the Trans-Blot Turbo Transfer System (BIO-RAD) for 10 minutes.
The membrane was blocked in 5% milk in TBST for 1 hour before incubating with
RPRD2 primary antibody and 3% BSA overnight at room temperature on a rocking platform.
The primary antibody for RPRD2 was made using a 1:2000/2.5% BSA dilution (17.5 μl and 35
ml) with the primary Ab10363, Goat pAb to RPRD2 50 ug (1mg/mL) (Abcam). The following
morning, the membrane was washed with TBST with extra Tween 20 and incubated with the
secondary antibody and 2.5% milk with TBST. Secondary antibodies for RPRD2 were made
using 5 μl of Dnk pAb to Goat IgG 500 ug 2mg/ml and 50 ml of 2.5 % milk in TBST. After five
more washes on the rocking platform, the membrane was exposed to Clarity ECL substrate
(BIO-RAD; catalog number 170-5060) and developed in the ChemiDoc MP instrument. Using
the Image Lab Software, RPRD2 band intensity could be quantified and normalized to the
presence of Beta-Actin in the lane.
This process was repeated to visualize the band intensity of GFP, pSer5 and RNA Pol II
in the membrane and that data was normalized to the total protein level. Primary antibodies for
GFP were made with the dilution 1:10000/2.5% BSA with the primary mouse mAB
(Proteintech). Primary antibodies for pSer5 and Pol II were made with the dilution of
1:1000/2.5% BSA (35 μl and 35 ml) with the primary Rb pAb to RNA polymerase II CTD repeat
YSPTSPS (pSer5) and Rb pAb to RNA polymerase II CTD repeat YSPTSPS, respectively
(Abcam). After the primary antibody was added, the membrane was placed on a rocking
platform in the cold room (40 C) overnight. The membrane was washed three times with TBST,
then the secondary antibody was added to the membrane. Secondary antibodies for GFP were
made with 5 μl of anti-mouse-HRP with 50 ml of 2.5% milk in TBST. Secondary antibodies for
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pSer5 and RNA Pol II were made with 5 μl of anti-rabbit-HRP with 50 ml of 2.5% milk in
TBST. After one hour, the membranes were washed with TBST and could be developed in the
ChemiDoc instrument. RNA Pol II and GFP bands were then quantified through normalization
of the total protein in the band to Beta-Actin. pSer5 bands were quantified and normalized to the
expression of RNA Pol II in the membrane. Western blot and its analysis were performed with
the guidance of Xiaohong Cui, the laboratory technician, and the help of Claire Atiyeh.

Statistical Analysis
Statistics were performed in Prism version 9 for Windows (GraphPad Software, La Jolla,
CA). Unpaired t-tests were used for the comparison of groups that received HSV-RPRD2 or
HSV-GFP in the analysis of the SI, EPM and open field tests and Western blots. Two-way
ANOVAs were performed to analyze the effects of the two independent variables, viral injection
and exposure to CSDS, on the behavioral data. A Pearson’s correlation coefficient test was
performed to analyze the strength of relationship between RPRD2 expression and pSer5
expression and time spent in the open arms of the EPM. Outliers are identified by using the
robust regression and outlier removal (ROUT) test and are excluded from the study when
applicable. Samples that did not express GFP upon tissue analysis are also excluded from the
study. Significance is reported at p<0.05.
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Results
Injection of HSV-RPRD2 to the NAc does not influence social behavior.
In the SI test, unpaired t-tests showed no difference between mice who were injected with
HSV-RPRD2 and those that were injected with HSV-GFP in individual groups (p>0.05). There
was no difference in the number of resilient mice or the number of susceptible mice between the
two groups. The SI ratios were calculated by dividing the time that the C57BL/6J mouse spent in
the interaction zone while the target was present by the time spent in the interaction zone while
the target was absent. A two-way ANOVA found no statistical significance between mice who
were exposed to CSDS or not (stressed or unstressed) or in mice who received HSV-RPRD2 in
comparison to HSV-GFP (p=0.8837; p=0.9085) (Figure 4). No differences were seen between
groups that experienced accelerated CSDS or the group that did not experience CSDS (Figure
4). There was no significant interaction between these two variables. In addition, the injection of
HSV-RPRD2 did not impact the SI ratio significantly from the control groups. From these data,
it can be concluded that HSV-RPRD2 had no significant effect on social behavior as tested in
this task, regardless of the influence of CSDS.

HSV-RPRD2 shows no significant effect in time spent in the center of the open field test.
Mice who were injected with HSV-RPRD2 in the NAc spent a similar time in the center
of the field as the control group (Figure 5A). A two-way ANOVA analyzed that this data is not
significant between mice injected with HSV-RPRD2 and mice injected with HSV-GFP
(p=0.1484). CSDS does not appear to have an effect on this behavior based on this data
(p=0.2318). The interaction between these two variables was not significant. Distance traveled in
34

the open field was similar between all mice, regardless of viral injection or CSDS (p=0.3735;
p=0.3992) (Figure 5B). Mice that spend increased time in the center show a tendency known as
thigmotaxis, or staying near the walls in an open field, which is an indicator of increased anxietylike behavior. This data is not significant, it cannot be concluded that HSV-RPRD2 in the NAc
had an influence on the behavior of mice to avoid the center of the field.

EPM test shows significant difference in time spent in open arms, but not distance traveled.
A two-way ANOVA revealed that mice injected with HSV-RPRD2 in the NAc spent
significantly (p=0.0332) less time exploring the open arms of the maze in comparison to the
control group (Figure 6A). Mice that experienced stress (CSDS) also spent significantly less
time in the open arms of the EPM than the unstressed group (p=0.0265). The interaction between
these two terms was not significant. The distance traveled by the mice in both the RPRD2 group
and the GFP group was not significant (p=0.0849) and was not influenced by exposure to CSDS
(p=0.1327) (Figure 6B). The injection of HSV-RPRD2 does not affect the total movement of
mice in the field. The data from the EPM shows that mice injected with HSV-RPRD2 in the NAc
spend significantly less time in the open arms of the EPM, indicating greater anxiety-like
behavior. Since this phenotype was observed even in mice that had not previously experienced
CSDS, it can be inferred that RPRD2 overexpression in the NAc is singularly sufficient to
manifest anxiety-like behaviors.

Western blot analysis of RPRD2, pSer5, and Pol II data.
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Western blot analysis was performed on two of the subject groups: the group that had no
CSDS and the group that had a 5 day accelerated CSDS. Normalization of Western blot data
used Image Lab Software (BIO-RAD) to quantify the bands of RPRD2, Ser5, RNA Pol II, or
GFP and divide it by the quantified band of the loading control B-Actin (molecular weight=42
kDa). Normalization makes it possible to accurately analyze the protein levels within the
membrane and minimizes any variances between samples that may be present.
RPRD2 has a molecular weight of about 220 kDa as seen on the membrane of Western
blots from the tissue samples of the mice (Figure 7A). Normalization of RPRD2 to the control
B-Actin shows no difference in expression of RPRD2 in mice that received HSV-RPRD2 in
comparison to the control group (Figure 7B). An unpaired t-test shows that this data is not
significantly different (p=0.2494), but this data may be affected by external factors such as
accuracy of NAc microdissection, in vivo regulation of RPRD2 protein levels, and the HSVmediated overexpression of RPRD2 being restricted to neurons in the NAc. However, future
studies should be performed to determine that levels of RPRD2 are higher in the membrane of
mice that receive the viral vector and different methods may be required to get more accurate
results.
The molecular weight of RNA Pol II pSer5 is about 250 kDa and is observed on the
membranes of the Western blot (Figure 9A). Normalization of RNA Pol II pSer5 to RNA Pol II
reveals no difference in expression of pSer5 in the NAc of mice who received HSV-RPRD2
(Figure 9B). An unpaired t-test reveals that this data is not significant (p=0.5679). A decrease in
pSer5 expression in mice injected with HSV-RPRD2 would allude to a potential mechanism for
RPRD2, but no conclusions can be drawn based on the preliminary data from this thesis.
However, further studies would be required to provide more clarification.
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Pol II has a molecular weight of about 250 kDa on the membrane of the Western blot
(Figure 10A). The normalization of Pol II to B-Actin shows no difference between the two
subject groups. An unpaired t-test shows that this data is not significant (p=0.4665) (Figure
10B). Mice injected with HSV-RPRD2 in the NAc do not have significantly different levels of
Pol II in comparison to the control group.
GFP has a molecular weight of about 27 kDa on the membrane of the Western blot
(Figure 12A). The normalization of GFP to B-Actin shows no difference between the two
subject groups injected with either HSV-RPRD2 or HSV-GFP. An unpaired t-test shows that this
data is not significant (p=0.5328) (Figure 12B). This graph confirms the presence of the virus in
the NAc tissue and shows no significantly different levels of GFP present between the two
groups.

Correlation graphs between RPRD2 expression and anxiety behavior shows no significant
relationship.
A correlation graph between the two variables RPRD2 expression normalized to B-Actin
and anxiety-like behavior, as shown by time spent in the open arms of the EPM, shows no
significant relationship (Figure 8). A Pearson correlation coefficient was found to be -0.03417
and the p value was calculated to be not significant (p=0.8577). The simple linear regression of
the graph shows the equation is y=-1.048*X+32.92. The data indicates no significant correlation
between the levels of RPRD2 present in the NAc and the anxiety-like behavior of time spent in
the open arms of the EPM.

37

Correlation graphs between RPRD2 expression and pSer5 expression show no significant
relationship.
A correlation graph between the two variables RPRD2 expression and pSer5 expression,
both normalized to B-Actin, shows no significant relationship (Figure 11). A Pearson correlation
coefficient was found to be 0.05162 and the p value was calculated to be not significant
(p=0.7827). The simple linear regression of the graph shows the equation is y=0.06618*X+1.09.
This data indicates that there is no significant correlation between the levels of RPRD2 present in
the NAc and the levels of pSer5 present in the membrane.
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Figure 4: HSV-RPRD2 does not influence social behavior, regardless of CSDS. No significant
difference was observed between social interaction ratios of HSV-GFP and HSV-RPRD2,
irrespective of whether groups experienced CSDS. SI ratio greater than 1 indicates a resilient
mouse and SI ratio less than 1 indicates a susceptible mouse. Each group had roughly equal
amounts of resilient and susceptible mice, indicating that HSV-RPRD2 had no effect on social
behavior. Data is from 5 day CSDS, 6 Day CSDS, and 0 day CSDS (Figure 2). HSV-GFP n=23;
HSV-RPRD2 n=22. One HSV-GFP mouse was identified as an outlier (5 day CSDS, ROUT Q =
1%) and excluded. Symbols represent mean ± SEM.
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Figure 5: HSV-RPRD2 shows no significant effect in time spent in the center of the open field
test. A) The time spent in the center of the field of mice injected with HSV-RPRD2 is not
significantly different from the control group HSV-GFP. This behavior is not influenced by the
experience of CSDS. B) Distance traveled in the open field is not modified by HSV-RPRD2
injection. Data is from 5 day CSDS, 6 Day CSDS, and 0 day CSDS (Figure 2). HSV-GFP n=24;
HSV-RPRD2 n=22. Symbols represent mean ± SEM.
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Figure 6: HSV-RPRD2 spent significantly less time in the open arms of the EPM, but not
distance traveled. A) HSV-RPRD2 injected mice spend significantly less time on the open arms
than the control group (p=0.0332). Mice who were stressed through CSDS spent significantly
less time on the open arms (p=0.0265), though the interaction between these terms was not
significant. B) No significant difference in distance traveled on the EPM between groups was
found to be influenced by viral injection of RPRD2 or GFP or exposure to CSDS (stressed or
unstressed) (p=0.0849; p=0.1327). Data is from 5 day CSDS, 6 Day CSDS, and 0 day CSDS
(Figure 2). HSV-GFP n=24; HSV-RPRD2 n=22. Asterisks indicate effects with p<0.05.
Symbols represent mean ± SEM.
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Figure 7: RPRD2 Western blot data. A) Western blot for RPRD2 on membrane and B-Actin. B)
Relative expression of RPRD2 normalized to B-Actin shows increased RPRD2 in the NAc has a
trend of increased RPRD2 expression in the membrane (p=0.2494). Data is from 0 day CSDS
(Figure 2). HSV-GFP n=8; HSV-RPRD2 n=6. One HSV-GFP mouse was identified as an outlier
(0 day CSDS, ROUT Q = 1%) and excluded. Symbols represent mean ± SEM.
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Figure 8: Correlation between level of RPRD2 expression and time spent in the open arms of the
EPM shows no significant relationship. Correlation graph of RPRD2 expression normalized to
B-Actin compared to the time the mouse spent in the open arms of the EPM shows no
relationship between the two variables. Pearson’s correlation of RPRD2 to time in the open arms
of the EPM = -0.03471. Data is from 5 day CSDS and 0 day CSDS (Figure 2). n=31. Line
represents simple linear regression.
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Figure 9: Pol II pSer5 Western blot data. A) Western blot for Pol II pSer5 on membrane and
RNA Pol II. B) Relative expression of Pol II pSer5 normalized to RNA Pol II shows no
difference in Pol II pSer5 expression in the membrane (p=0.5679). Data is from 5 day CSDS and
0 day CSDS (Figure 2). HSV-GFP n=17; HSV-RPRD2 n=15. Symbols represent mean ± SEM.
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Figure 10: RNA Pol II Western blot data. A) Western blot for RNA Pol II on membrane and BActin. B) Relative expression of RNA Pol II normalized to B-Actin shows no significant
difference between groups. Data is from 5 day CSDS and 0 day CSDS (Figure 2). HSV-GFP
n=17; HSV-RPRD2 n=15. Symbols represent mean ± SEM.
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Figure 11: Correlation of expression of RPRD2 to expression of pSer5 shows no significant
relationship. Correlation graph of RPRD2 expression normalized to B-Actin compared to the
pSer5 expression normalized to B-Actin shows no relationship between the two variables.
Pearson’s correlation of RPRD2 to pSer5 = 0.065162. Data is from 5 day CSDS and 0 day CSDS
(Figure 2). n=31. Line represents simple linear regression.
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Figure 12: GFP Western blot data. A) Representative Western blot for GFP on membrane and
B-Actin. B) Relative expression of GFP normalized to B-Actin shows no significant difference
between groups. Data is from 5 day CSDS and 0 day CSDS (Figure 2). HSV-GFP n=16; HSVRPRD2 n=15. One HSV-GFP mouse was identified as an outlier (5 day CSDS, ROUT Q=1%)
and excluded from this figure. Symbols represent mean ± SEM.
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Discussion
Research focused on the potential mechanisms of anxiety disorders are needed for the
discovery of improved therapies and treatments. Due to the increased rate of diagnosis of these
disorders all around the world, it is imperative to pursue further knowledge of the complex
intricacies of anxiety disorders. While RPRD2 has limited research, its potential interaction with
the CTD of Pol II and its effect in resilient mice from previous studies led to this thesis to
observe its specific effects (Hamilton et al., 2020; Ali et al., 2019; Ramani et al., 2021). While
the initial hypothesis of this study anticipated increased expression of RPRD2 would result in
mice resilient to CSDS, the results of this study demonstrate that injection of HSV-RPRD2 in the
NAc induces anxiety-like behavior in mice. Whether similar mechanisms occur in humans
suffering from anxiety disorders remains to be seen.

Injection of HSV-RPRD2 into the NAc did not impact social behavior
The original hypothesis of this thesis project was that higher levels of RPRD2 would
induce resilience in mice exposed to CSDS and would have an SI ratio greater than one, based on
previous results from the lab (Hamilton et al., 2020). However, the data from the behavior
analysis of the mice following an accelerated CSDS consistently revealed no difference between
the group that received HSV-RPRD2 and the group that received HSV-GFP, in terms of social
metrics (Figure 4). There were equal amounts of mice with an SI ratio greater than one and an SI
ratio less than one in both groups, showing that the original hypothesis must be rejected. In
addition, the mice who did not experience CSDS were not more susceptible than the other
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groups, which may signify that the accelerated CSDS protocol did not stress the C57BL/6J mice
enough.
There are no current studies that focus on the relationship between RPRD2 and social
behavior, but the data from this project leads us to conclude that viral RPRD2 injection into the
NAc has no influence on social behavior in mice regardless of CSDS. The protein likely does not
play a role in the influence or reinforcement of social behavior in mice. Other compensatory
mechanisms were likely responsible for the increase in levels of RPRD2 seen in the NAc in the
preliminary data from our group (Hamilton et al., 2020). The injection of HSV-RPRD2
consistently had no effect on the SI ratio of C57BL/6J mice and is not affected by CSDS
differently than mice injected with HSV-GFP.

HSV-RPRD2 induces anxiety-like behavior in mice
The injection of HSV-RPRD2 to the NAc induced anxiety-like behaviors in mice. Mice
that received HSV-RPRD2 spent significantly less time in the open arms of the EPM (Figure
6A), signifying increased anxiety-like in these animals in comparison to the HSV-GFP group
(Kraeuter et al., 2019; Campos et al., 2013). An interesting note from the study is that after mice
were single-housed after CSDS, there were four mice who received HSV-RPRD2 who did not
make their “beds,” while all other mice did (data not shown). This may be an additional marker
of anxiety in this group of mice. Further data and repeated studies may find consistent results
with this study.
The NAc is thought to be a major part of the pathophysiology of multiple mental illnesses
due to its role in the reward processing of the brain. The NAc is critical in influencing motivated
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behaviors, including those to avoid potential stressors or negative stimuli (Levita et al., 2012).
Increased levels of RPRD2 in the NAc may work to increase the animal’s aversion to anxietyprovoking stimuli such as an open, elevated space in the EPM. While the stereotaxic surgery
performed in this project did not specifically target the shell or the core, the injection of HSVRPRD2 likely causes a disruption or imbalance in the NAc that alters the processing of
motivation.

Effects of RPRD2 on female mice
This study observed the effects of viral injection of HSV-RPRD2 in the NAc of only
male C57BL/6J mice. This project utilized male mice to determine the effects of increased
expression of RPRD2 within the NAc on accelerated CSDS because male CD-1 aggressors will
not defeat female mice without modifications to either the female mouse or the CD-1 (Franco et
al., 2022). Since results found the onset of anxiety-like behaviors in unstressed adult males
injected with virla RPRD2, this study could be replicated in adult female mice to determine if
RPRD2 has comparable effects on both sexes. If this study were repeated with female mice,
similar results of an increase in anxious behavior after RPRD2 injection into the NAc would be
anticipated. The hypothesis for that study would be that increased levels of RPRD2 in the NAc
would increase anxiety-like behaviors different in female than male mice, such as decreased time
in the open arms and thigmotaxis in female C57BL/6J mice.
Since females are significantly more likely to be affected by anxiety in human subjects
(Bandelow & Michaelis, 2015), female C57BL/6J mice may experience more pronounced
anxiety-like behaviors than the male subjects. However, this protein currently has no established

59

effects in female mice since research on RPRD2 is so limited as of date. Future studies that use
female mice will be imperative to the development of anti-anxiety treatments that target RPRD2,
especially if these studies yield significant data. Research on both male and female mice can
allow for a better understanding of RPRD2 and is crucial to learning the mechanism of action for
this protein and anxiety behaviors.

Limitations of HSV-RPRD2 expression in the NAc
From the Western blots that were analyzed, there was no significant difference in RPRD2
levels between the two groups (Figure 7B). The group injected with HSV-RPRD2 did not have a
significantly higher presence of the protein RPRD2 in the PVDF membrane than the control
group that just received HSV-GFP. From the tool that was created (Figure 1) and the anxietylike behavior in mice who received the RPRD2 virus seen in the EPM, it is possible that other
factors are at play that account for the insignificant difference in expression of RPRD2 between
the two subject groups of mice.
HSVs are effective in targeting neurons and are a non-genome inserting virus that can
package large plasmids. However, it has a very short expression period of roughly three days,
and after this period, HSV cannot be identified reliably within the neurons (Lachmann, 2004).
This may contribute to the lower expression of HSV-RPRD2 recorded in Figure 7. In addition,
the dispersion of RPRD2 and the ambiguity of the punches from the brain tissue may have led to
less accurate data in Western blot analysis. While Western blots are extremely accurate in
detecting proteins present in tissue, the data may not have reached significance due to the
repression of the virus, the dispersion of RPRD2 throughout the brain region, and the size of the
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punches taken from the NAc. HSVs specifically target neurons, but it is unknown which cell
type in the NAc is driving this behavioral response. Further studies should be conducted to
confirm an overexpression of the presence of RPRD2 in the NAc. In addition, future studies
should be performed to confirm the specificity of the RPRD2 antibody used in this thesis to
confirm its validity.

Limitations of Targeting the NAc in Stereotaxic Surgery
The stereotaxic surgery performed in this thesis project did not specifically target the
shell or the core of the NAc. As previously mentioned, the shell and the core are molecularly
diverse from each other and have different functions with the shell more focused on emotional
and motivational responses and the core involved in learning and goal-directed behaviors (Baik,
2020). The core and the shell have considerable differences in connectivity. Dorsal regions of the
medial prefrontal cortex innervate the core while the shell receives afferents from ventral regions
of the medial prefrontal cortex (Feja et al., 2014). In addition, the core sends efferent signals to
the basal ganglia while the shell projects to subcortical limbic structures (Feja et al., 2014). The
differences in connectivity leads to the functional dichotomy of these two regions that cause
distinct and unique responses to anxiety provoking stimuli.
Since this study did not specifically target the core or shell of the NAc, it is unknown
which region of the NAc is driving the anxiety-like behavior seen in mice injected with viral
RPRD2. In addition, since the stereotaxic surgery was non-specific, it may have resulted in a
bimodal distribution of the virus throughout the NAc. This may provide another reason that there
was a high degree of variance in the behaviors observed in the C57BL/6J mice as well as the
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variation in Western blot analysis of expression levels of HSV-RPRD2 in the NAc tissue. Future
studies should observe the behavior induced by overexpression of RPRD2 while focusing on
targeting an individual region of the NAc.

Proposed mechanism of action for RPRD2
Based on the knowledge of the RPRD family of proteins, another aim of this thesis
project was to propose a potential mechanism for how this protein can influence anxietybehavior. Prior studies have shown that RPRD family proteins contain CIDs that can influence
transcription, so this thesis focused on RPRD2 and its influence on Pol II Ser5 (Ali et al., 2019).
To do so, the level of Pol II and pSer5 was analyzed through Western blots of tissue from mice
injected with HSV-RPRD2 and HSV-GFP and compared (Figures 9 and 10). The data showed
no significant difference in the level of pSer5 in the NAc of mice who received HSV-RPRD2
(Figure 9). On the basis of the data collected and prior knowledge of the protein, the mechanism
that upregulated RPRD2 lowers the levels of pSer5 in the PVDF membrane could not be
validated.
RPRD2 binds to the CTD of Pol II to influence Ser5 phosphorylation (Figure 13). The
protein then dephosphorylates, which causes transcription to pause (Figure 14B). Pol II is unable
to progress into the elongation phase of transcription until Ser5 can be re-phosphorylated and
RPRD2 is removed from the CTD. The interaction with the phosphorylation of the CTD is a
rate-limiting step that is critical in an accurate transcription and cell survival (Winczura et al.,
2021). This thesis was hoping to support previous research (Ali et al., 2019) that suggests that
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proteins from the RPRD family can dephosphorylate the CTD and downregulate transcription,
but no conclusions can be drawn from the data recorded from this study.
It is important to note that the limitations previously mentioned affected the expression of
pSer5 and Pol II in the NAc tissue. HSVs infect neurons, but they are short lasting and typically
only express in the membrane for three days. It is difficult to determine if the samples were taken
at the proper time that RPRD2 would have an effect on pSer5. Future studies should consider
more specific targeting in the brain and other measures that can be used to determine protein
expression such as IHC or PCR. The data performed in this study was not significant, but future
studies would likely confirm this mechanism.

Conclusions and Future Directions
This thesis project determined that RPRD2 injected into the NAc significantly increases
anxiety-like behavior in C57BL/6J mice, regardless of exposure to CSDS. Injection of viral
RPRD2 increased anxiety-like behaviors such as avoidance of the open arms of the EPM in
comparison to mice who received the control HSV-GFP. RPRD2 did not have any effect on
social behavior and did not impact the SI ratio of mice that experienced an accelerated CSDS.
The increased anxiety-like behaviors observed may occur through RPRD2’s interaction with the
CTD of Pol II, where it binds to pSer5 and dephosphorylates it. This prevents Pol II from
progressing into the elongation phase of transcription until RPRD2 can be removed and Ser5 can
be phosphorylated again.
The current understanding is that RPRD2 induces anxiety-like behavior through pausing
transcription by dephosphorylating Ser5 on the CTD of Pol II in the NAc. While prior studies
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from this group (Hamilton et al., 2020) showed that RPRD2 was higher in the NAc of animals
resilient to CSDS, the data from this thesis indicates that other brain mechanisms are likely
responsible for this effect and not the protein of interest. Mice injected with HSV-RPRD2
displayed greater anxiety-like behaviors than mice injected with HSV-GFP across the behavioral
data that was analyzed. The study of this protein can lead to more effective anti-anxiety
treatments through confirming its mechanisms in the brain. The development of new treatments
that target this mechanism should reduce levels of RPRD2 in the brain in order to reduce
symptoms of anxiety. However, significant research must be performed prior in furtherance of
gaining a more comprehensive understanding of this protein and its role in anxiety behaviors.
The protein of interest from this study, RPRD2, currently has very limited research.
There are no current studies that link this protein to organismal behaviors. Future studies should
reinforce that RPRD2 has an effect on anxiety-like behaviors and further explore its relationship
with depression, social behaviors, and stress. Since females are more affected by anxiety
disorders than males, it would be advantageous to study the effects of RPRD2 on female
C57BL/6J mice. This study focused solely on the NAc, and other brain regions may be
worthwhile to study. Further projects should also confirm a significant increase in the levels of
RPRD2 in tissue after viral injection, perhaps through immunohistochemistry (IHC) instead of
Western blot analysis. IHC can detect the exact location of a target protein within a tissue
sample, which may be beneficial in determining shell versus core expression of HSV-RPRD2
(Kaliyappan et al., 2012). Additional studies should also confirm the mechanism of action for
RPRD2 with the ultimate goal of developing a treatment to reduce anxiety behaviors.
In conclusion, this thesis provides a novel perspective that RPRD2 induces anxiety-like
behavior in male C57BL/6J mice when injected in the NAc. The accelerated CSDS paradigm did
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not have any apparent effects on mice injected with this virus and social behaviors were not
significantly impacted. The Western blot analysis of brain tissue from the NAc hinted at a
potential mechanism for RPRD2 to induce anxiety-like behaviors by pausing transcription, but
no significant data was recorded. While there are currently no studies that have researched a
relationship with RPRD2 and anxiety behaviors, future studies should focus on this protein to
better understand its effects and its mechanisms in order to produce more effective, long-lasting
treatments for anxiety disorders.
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Figure 13: Proposed mechanism of RPRD2. RPRD2 binds to a phosphorylated Ser 5 on the
CTD of RNA Pol II. RPRD2 then dephosphorylates Ser5 and pauses transcription by preventing
RNA Pol II from moving forward. Created with BioRender.com.
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Figure 14: RPRD2 pauses transcription. A) TFII factor -D recognizes the promoter region of the
DNA and binds to the TBP to form a transcription-initiation complex. Transcription can be
initiated, and Pol II progresses into the elongation phase and produces mRNA. B) RPRD2 binds
to pSer5 on the CTD of Pol II, dephosphorylates it, and prevents Pol II from progressing into
elongation phase. C) Key of protein factors in the transcription complex. Created with
BioRender.com.
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